H63D- and Oshtoran Syndromes: the silent murderers

Understanding H63D Syndrome: A Comprehensive Overview

This lecture introduces and describes H63D Syndrome Type-1, a distinct and serious clinical condition linked to a homozygous H63D mutation of the HFE gene. Unlike typical hemochromatosis, which involves high ferritin, this syndrome is characterized by low transferrin and high transferrin saturation, leading to the formation of toxic non-transferrin-bound iron (NTBI). NTBI accumulation, particularly in brain structures like the substantia nigra, triggers oxidative inflammation and causes a range of neurological symptoms, including movement disorders, cognitive impairment, and sleep disturbances, alongside issues in other organ systems. Diagnosis relies on specific lab findings and genetic testing for the homozygous mutation, but no causal treatment exists currently, with management focusing on dietary iron control and symptomatic relief.

H63D- and Oshtoran Syndromes: the silent murderers

A deadly disease, missed in 95% of the patients with a highly typical lab iron status. This podcast might save your health and early death. Transferrin ↓ - Transferrin Saturation high ↑ - Ferritin ↓

Oshtoran Syndrom - A highly dangerous Syndrome

A conference report from the International Research Consortium for H63D Syndrome highlights the critical need for medical professionals to recognize Oshtoran Syndrome, also known as H63D Syndrome Type-3, a severe and often misdiagnosed genetic disorder. Despite a low number of confirmed diagnoses, experts believe the actual prevalence is much higher due to the subtle and varied symptoms. The syndrome is characterized by a specific iron profile – low ferritin, elevated transferrin saturation, and hypotransferrinemia – leading to dangerous accumulation of non-transferrin-bound iron (NTBI) in organs. Early detection is crucial for preventing significant organ damage, which can impact the brain, heart, liver, skin, and reproductive organs, potentially causing life-threatening complications and immune system dysregulation. The consortium urges increased awareness and education among doctors and the public regarding this serious condition linked to the homozygous HFE gene H63D mutation, which has historically been incorrectly considered harmless.

H63D Syndrome killed Michael almost silently

This text tells the tragic true story of Michael, who has suffered since his youth from a multitude of severe and progressive neurological and physical symptoms that were misinterpreted and psychologized by doctors for decades. Only after thirty years is a homozygous mutation of the HFE gene H63D identified as the cause of his complaints, leading to what is called H63D syndrome. This rare syndrome, characterized by the accumulation of toxic non-transferrin-bound iron (NTBI), differs from classical hemochromatosis and is unknown to most physicians. The author criticizes the inertia of the medical system, the lack of interdisciplinary communication, and the disinterest in rare diseases that offer no financial incentives, emphasizing the necessity for patients and their families to become experts themselves.

Adult PANS and PANDAS patients: Sentinels for Infections?

This report focuses on the progressive manifestations of PANS and PANDAS in adults, extending beyond the primary identification of these conditions in children. It describes the clinical features, pathophysiological mechanisms, diagnostic considerations, and therapeutic approaches for both syndromes, which are characterized by the acute onset or exacerbation of neuropsychiatric symptoms, often associated with an immunological trigger. A case report illustrates how a patient’s PANDAS symptoms intensify as an “immune signal,” even before the visible onset of an infection. The authors emphasize the need for further research on these adult manifestations, particularly outside the USA and Asia, to gain a deeper understanding of the underlying mechanisms.